U.S. Markets closed

Electromedical Technologies, Inc. (EMED)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0480-0.0059 (-10.95%)
At close: 3:58PM EDT
Full screen
Loading interactive chart...
  • New Sales Initiatives and Executive to Aid in Driving Electromedical Technologies Revenue
    GlobeNewswire

    New Sales Initiatives and Executive to Aid in Driving Electromedical Technologies Revenue

    - Company adds New Sales Director with 12 years of Experience Selling and Training the Wellness Pro+ - Kathy Strand, R.N. has Sold Over 3,000 Wellness Pro+ Devices and Treated 28,000+ Patients - EMED Plans to On-Board 200 Active Sales Distributors by Year-End SCOTTSDALE, Ariz., May 06, 2021 (GLOBE NEWSWIRE) -- Electromedical Technologies, Inc. (OTCQB: EMED) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+® is pleased to announce that the Company has retained Kathy Strand, R.N. as its Director of Sales and Training. Ms. Strand is a Registered Nurse with twelve years of experience in selling more than 3,000 units of the Company’s flagship device – the WellnessPro+, and treating over 28,000 patients. Ms. Strand first learned about the Company and the WellnessPro+ when her mother was diagnosed with incurable and intractable pain, more than twelve years ago. Echoing the stories of many other users of the WellnessPro+, doctors informed Ms. Strand and her family that there was nothing that could be done to relieve her mother’s pain, except through the use of prescription opioids. After Ms. Strand learned about the WellnessPro+, her mother began treatments which resulted in immediate and life changing pain relief. Ms. Strand joined the Wellness Pro+ community and became a sales representative and evangelist for the Company. Ms. Strand has advised patients, doctors, therapists, professional sports teams, schools and university athletic departments, hospitals, and animal therapy departments on its use, with outstanding sales success, led by favorable patient outcomes. As the Director of Sales and Training for EMED, Ms. Strand will be responsible for sales of the Wellness Pro+, collaborating with leadership on the Company’s social media efforts and outreach. Ms. Strand’s sales focus will include educating the public on the benefits of use of the Wellness Pro+ and engaging NEW WellnessPro distributors in every state. Ms. Strand will also actively host weekly educational training sessions and ongoing support meetings to help new customers use their new WellnessPro+ units. The Company expects that these initiatives will help drive product awareness and new sales of the WellnessPro+. As awareness of the product’s effectiveness in relieving intractable pain increases, the Company plans to add new sales representatives and distributors to meet potential increases in demand. Matthew Wolfson, Founder and CEO of EMED, noted, “We are excited to have Kathy part of our team and as our first sales director. She is the natural choice to lead our efforts given her medical background and medical device market experience. Plus, her success in selling the WellnessPro+ speaks for itself. She has sold around 3,000 WellnessPro devices since she joined our company in a sales representative/distributor role over 10 years ago. Her ability to drive sales though training and social media are critical cogs in our 2021 distributor and sales expansion plans. By year-end, we plan to have at least 200 active distributors. We have already on boarded 37 NEW distributors this year and we haven’t even fully commenced our distribution program. Thus, we expect meaningful product sales from these channels and additional distributors may occur in the second half of 2021.” Kathy Strand commented, “I have participated in dozens of trade shows and have seen many of the devices out there in the market today - this device helped thousands of people get their lives back and feeling good again. I have never seen a more effective device to battle chronic pain. I believe that the WellnessPro + is the best there is on the market today!” About Electromedical Technologies Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses, the Company’s goal is to reduce pain and improve overall human wellbeing. The Company’s current FDA cleared product indications are for chronic, acute, post traumatic and post-operative, intractable pain relief. For more information, please visit www.electromedtech.com. Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Corporate Contact: Electromedical Technologies, Inc.Hanover InternationalTel: 1.888.880.7888email: ir@electromedtech.com https://electromedtech.com

  • Electromedical Technologies Enters Phase 2 of Prototype development on WellnessPro POD™
    GlobeNewswire

    Electromedical Technologies Enters Phase 2 of Prototype development on WellnessPro POD™

    - Efficacy and Product Integration Testing Slated for Completion in Fall 2021 - Upon FDA Clearance the WellnessPro POD™ Device Could Emerge as a Leading Chronic Pain drug-free choice to Opioids for Mass Market Retail Customers. SCOTTSDALE, Ariz., April 20, 2021 (GLOBE NEWSWIRE) -- Electromedical Technologies, Inc. (OTCQB: EMED ) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+Plus® is pleased to announce that the Company has entered into Phase 2 of prototype construction of the new WellnessPro POD™. The second phase of the process features overall efficacy and product integration testing and is slated to be completed in the Fall 2021. Once complete, the device will be used in a 510(k) medical device submission with the U.S. Food & Drug Administration (FDA). WellnessPro POD™ is positioned as a new, smaller, professional grade wearable device for mass market retail customers seeking non-opioid therapy to treat chronic pain, and has the ability to work with the Company’s flagship WellnessPro+Plus® device. Chronic and acute pain sufferers around the world are actively seeking non-opioid alternatives to treat their conditions, especially during the COVID-19 pandemic, as noted in a recent article titled “COVID-19 and the Opioid Crisis: Dueling Epidemics Illustrate the Need for Future Action” that was written by Lauren Biscaldi and published April 15, 2021 in Neurology Advisor. (https://www.neurologyadvisor.com/topics/pain/two-concurrent-health-emergencies-covid-19-and-the-opioid-crisis/) Leveraging the Company’s drug free, non-invasive, non-toxic method to treat pain, Electromedical Technologies has seen strong sales of its current bioelectronics device and upon FDA clearance, is positioned to increase its market share via its mass market-designed WellnessPro POD™. Matthew Wolfson, Founder and CEO of Electromedical Technologies , Inc (OTCQB: EMED), noted, “We have the ability to help people live pain free and are pleased that the Company has entered this critical accelerated phase of the development process for our new bioelectronics device that will be geared toward retail mass market. We understand that with COVID-19 and the overall opioid crisis in general, there is a strong need to help patients suffering from chronic and acute pain without causing addiction. We truly believe that our Company’s products, especially a retail version, will position EMED to be the go-to safe, non invasive drug free choice to opioids and allow us to enter into a whole new market. Bioelectronics is the future of medicine and this is why major companies like Google, GSK and other top pharmaceutical companies are investing heavily into this space!” About Electromedical Technologies Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through University collaboration agreements, the Company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body. By studying the impacts of electrical fields in cell signaling and immune responses, the Company’s goal is to reduce pain and improve overall human wellbeing. The Company’s current FDA cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief. For more information, please visit www.electromedtech.com. Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Corporate Contact: Electromedical Technologies, Inc.Hanover InternationalTel: 1.888.880.7888email: ir@electromedtech.com https://electromedtech.com

  • Electromedical Technologies, Inc. Featured on The Big Biz Radio Show
    GlobeNewswire

    Electromedical Technologies, Inc. Featured on The Big Biz Radio Show

    CEO Matthew Wolfson recently Interviewed three times by Popular Media Host Bob “Sully” Sullivan on the Big Biz Radio ShowSCOTTSDALE, Ariz., April 13, 2021 (GLOBE NEWSWIRE) -- Electromedical Technologies, Inc. (OTCQB: EMED ) (the "Company"), a pioneer in the development and manufacturing of bioelectronic devices, including the FDA cleared WellnessPro+, is pleased to announce that CEO Matthew Wolfson has, in recent weeks, been a featured guest on the popular Big Biz Radio Show. The latest interview can be accessed here. Billed as “Business with a Bite”, the Big Biz Radio Show features fast-talking, hard-hitting discussions on business and finance. The show can be seen and heard weekdays on network television, including the YouTOO American Television Network, which reaches a large viewing audience. Moreover, host Bob “Sully” Sullivan is a weekly contributor on the FOX Business Network. After appearing three times over the past several weeks, Electromedical Technologies quickly became a favorite of the show. This opportunity enabled the Company to reach a wide audience with interests in new and developing companies and technologies, and especially gave the Company the opportunity to highlight the Company’s treatments for chronic pain, as well as fostering a greater awareness of the Company’s future operations and plans. In addition, Mr. Wolfson highlighted the Company’s new prototype bioelectronics device currently in development, the Wellness POD, which is expected to be completed later this year, and included in a 510(k) medical device submission with the FDA. The WellnessPlus POD is positioned as a new, smaller, professional grade wearable device for mass market retail customers, and has the ability to work with the flagship Wellness Pro+ device. Mr. Wolfson, noted, “We are delighted to have had the opportunity to tell our story directly to interested investors and prospective customers.” About Electromedical Technologies Headquartered in Scottsdale, Arizona, Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief. Our animal studies do not involve any human testing, and are not related to our current products. We are conducting this research to augment and advance the science of electro-modulation in healthcare. The United States Food and Drug Administration has not reviewed or approved our animal research studies. For more information, visit www.electromedtech.com. Safe Harbor Statement This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Corporate Contact: Electromedical Technologies, Inc.Matthew WolfsonTel: 1.888.880.7888email: ceo@electromedtech.comhttps://electromedtech.com